Activation of Macrophages Enhances Susceptibility to SARS-CoV-2 Antibody-Dependent Enhancement and Promotes **Damage to Downstream Epithelial Cells**



Jennifer K. DeMarco¹, William E. Severson¹, Daniel R. DeMarco², Jon D. Gabbard¹ and Kenneth E. Palmer¹ ¹Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, KY ²Eurofins Microbiology Laboratories, Louisville, KY



Background & Significance

The distinct shift in peripheral monocyte activation and infiltration of these cells into the respiratory tract observed in severe cases of COVID-19 suggests that like SARS-CoV, the acute respiratory distress syndrome (ARDs) observed in SARS-CoV-2 infections may result from damage to the respiratory epithelia by improperly activated macrophages (MPs). In this study, we examined the ability of non-neutralizing antibodies to sensitize MPs to killing by SARS-CoV-2, as well as the impact of these cells on downstream epithelial cells.



Methods

Viability and Infection Assays

Raw 264.7 cells were seeded into 96-well plates at a density of 1x10⁴/well and incubated overnight in the presence or absence of heat-inactivated LPS derived from either E. coli (EC) or S. enteritidis (Sal). Cells were then treated with non-neutralizing antibodies or vehicle control at the time of infection with SARS-CoV-2. Viability was assessed 48 hours post-infection by luminescence following the addition of CellTiter-Glo® (Promega).

Assessment of Viral Replication by qPCR

Raw 264.7 cells were seeded at a density of 1x106 cells/well in a 12-well plate and allowed to settle overnight. The following day, cells were infected with SARS-CoV2 with an MOI of 0.05 and incubated overnight at 37C with 5% CO2. Cells were lysed with Trizol and RNA extracted using a Direct-zol™-96 MagBead RNA miniprep kit (Zymo). Quantitative PCR was performed using the VIRSeek SARS-CoV2 assay (Eurofins Genescan Technologies, Freiberg, Germany)



Killing of MPs is Independent of Viral Replication

Sample ID Average Ct Naïve no virus ND Naïve+virus 26.6±0.2 Naïve+Ab+virus 28.4+1.85 27.27±0.9 LPS+virus I PS+Ab+virus 28+0.2

Figure 1 and Table 1. Exposure to SARS-CoV2 alone had little impact on Raw264.7 cells (n=17). The presence of non-neutralizing antibodies at a concentration of 6.25 ug/ml, SARS-CoV2 significantly reduced MP viability to 35.98% and 53.67%, respectively (p<0.0001 and p=0.0003, n=14). Surprisingly, despite significant cell death, no increase in viral replication was observed in any of the macrophage samples suggesting that killing of MPs by SARS-CoV2 iccurs thru an as yet unknown mechanism. Independent of viral replication

Anti-Nucleocapsid Enhances ADE in Activated MPs



Figure 2. Activation of MPs with Sal-derived LPS sensitized MPs to viral killing, even in the absence of non-neutralizing antibody (20.12% viability, p<0.0001, n=18). MP activation by both Sal and EC LPS further enhanced viral killing in the presence of anti-nucleocapsid, reducing cell viability to 12.21% (0.0001, n=18) and 6 46% (n<0 0001 n=18)

SNs from Activated Macrophages Enhance Killing of Vero E6 Cells by SARs-CoV2 No Virus 120 SARS-CoV2

Figure 3. Supernatants collected from naïve MPs subjected to ADE markedly increased the susceptibility of Vero e6 cells to SARS-CoV2 nearly 9.8-fold (p<0.0001, n=12). Similarly, supernatants from MPs sensitized to SARS-CoV2 thru activation with EC LPS and Sal LPS also increased viral killing of Vero e6, reducing cell viability to 13.03% (p<0.0022, n=8).

Discussion

- Macrophages are resistant to killing by SARS-CoV2 in the absence of non-neutralizing antibodies
- Antibodies that do not neutralize the RBD region of the spike protein renders macrophages susceptible to the virus
- Killing of MPs by SARS-CoV2 does not result from viral replication
- Activation of macrophages thru TLRs also enhances sensitivity to SARS-CoV2, suggesting that the underlying state of inflammation may also play a role in determining the severity of COVID-19
- MPs secrete as yet unknown factors that enhance susceptibility of VeroE6 cells to SARS-CoV2, providing a route thru which components from virus-activated MPs directly damage surrounding respiratory tissues in the later stages of SARS-CoV2 infection.
- Taken together, this suggests that the MAS-like syndrome observed in severe COVID-19 may result from improper processing of the virus in the presence of non-neutralizing antibodies

Results